Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With and Without Ribavirin in Protease-Inhibitors ("PI") Failures
Status:
Unknown status
Trial end date:
2019-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of triple therapy of AbbVie
adults with chronic hepatitis C virus ("HCV"), who have not responded to prior treatment with
protease inhibitors.
The "Triple therapy" of AbbVie attacks various sites of the viral genome, thus increasing the
potential efficacy of the treatment, especially for patients who have failed PI treatment.